DSC-PWI高级灌注指标用于成人脑肿瘤术前诊断
该回顾性单中心研究纳入219例成人脑肿瘤患者,采用同一检查中两种采集参数行DSC-PWI,提取8个血流与代谢指标。结果显示联合指标的诊断效能优于传统CBV,并在异质性参数与独立历史队列中保持稳定。
要点
- 高级血管与代谢灌注指标组合对主要成人脑肿瘤的鉴别效能优于传统CBV。
- 该联合方案在两种采集参数及模拟异质性条件下诊断效能未见显著下降。
- 报告可关注除CBV外的微血管及氧代谢指标,有助于术前多维度判别肿瘤类型。
核心结论
- 高级血管与代谢灌注指标可对肿瘤进行多维度刻画,其诊断效能和可重复性均优于传统CBV,并且受采集参数影响较小。
研究设计与样本
- 回顾性单中心研究,2023—2025年共纳入219例患者,其中101例胶质母细胞瘤、52例转移瘤、46例脑膜瘤、20例淋巴瘤。
- 每例患者均在术前同一次检查中行两次DSC-PWI采集,第一次为未预负荷高翻转角,第二次为预负荷中等翻转角。
- 从三维肿瘤掩膜中提取8个标准化指标,包括大血管指标CBV、CBF、MTT,微血管指标TTD、CTH、COV,以及代谢指标OEF、CMRO2。
- 以AUC-ROC评估诊断效能,比较两种同质采集参数场景和一种模拟异质性场景,并采用2015—2020年55例独立历史队列进行验证。
关键影像表现/征象
- 研究提取的指标反映肿瘤三维体积内的血流、微血管通过时间和氧代谢特征,可用于区分胶质母细胞瘤、转移瘤、脑膜瘤与淋巴瘤。
诊断标准与关键数值
- 联合指标中位AUC-ROC为0.88(0.87—0.90),不同采集参数场景间未见显著差异。
- 各鉴别组中位AUC-ROC为:淋巴瘤与胶质母细胞瘤0.90,转移瘤与胶质母细胞瘤0.79,胶质母细胞瘤与脑膜瘤0.91,淋巴瘤与转移瘤0.90,转移瘤与脑膜瘤0.82,淋巴瘤与脑膜瘤0.97。
- 传统CBV中位AUC-ROC为0.73(范围0.58—0.91),联合指标显著优于CBV,配对Wilcoxon检验p<0.001—0.04。
- 独立验证队列中联合指标中位AUC-ROC为0.82—0.85,各比较组AUC为0.79—0.98。
临床应用与阅片要点
- 对主要成人脑肿瘤的术前DSC-PWI评估,可结合CBV以外的微血管指标和氧代谢指标而非仅报告CBV。
- 该多指标方案在未预负荷高翻转角和预负荷中等翻转角条件下均适用,提示在参数不一致时仍具参考价值。
局限性
- 本研究为单中心回顾性设计,独立验证队列来自历史数据,存在真实世界参数异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: The diagnostic performance of dynamic-susceptibility-contrast perfusion-weighted-imaging (DSC-PWI) relies almost exclusively on cerebral-blood-volume (CBV), a biomarker considered highly dependent on acquisition parameters. We investigated whether integrating advanced vascular and metabolic perfusion biomarkers improves the presurgical diagnosis of brain tumors and whether these gains are maintained independently of acquisition parameters.
METHODS: Retrospective single-center study (2023-2025) including 219 patients (101 glioblastomas, 52 metastases, 46 meningiomas, 20 lymphomas) with a unique double acquisition, single-session presurgical DSC-PWI protocol (first, non-preloaded high-flip-angle, and second, preloaded intermediate-flip-angle, per patient). Using innovative clinical software, eight normalized metrics were extracted from three-dimensional tumor masks. Three macrovascular: CBV, cerebral-blood-flow (CBF), mean-transit-time (MTT). Three microvascular: time-to-drain (TTD), capillary-transit-time-heterogeneity (CTH), coefficient-of-variation-of-transit-times (COV). Two metabolic: oxygen-extraction-fraction (OEF), cerebral-metabolic-rate-of-oxygen (CMRO2). Performance was assessed by the area-under-the-receiver-operating-characteristic-curve (AUC-ROC) in three acquisition scenarios: two homogeneous and one simulated heterogeneous. Independent validation was performed using a historical cohort of 55 unseen patients (2015-2020).
RESULTS: Median AUC-ROC was 0.88 (0.87-0.90, without significant differences across scenarios). Specifically, the median AUC-ROCs per pair were: Lymphoma-Glioblastoma = 0.90, Metastasis-Glioblastoma = 0.79, Glioblastoma-Meningioma = 0.91, Lymphoma-Metastasis = 0.90, Metastasis-Meningioma = 0.82, Lymphoma-Meningioma = 0.97. These results outperformed the conventional cerebral blood volume (median 0.73, range 0.58-0.91; significant, paired Wilcoxon p < 0.001-0.04). Performance was preserved in the independent validation cohort despite its inherent real-world heterogeneity (median 0.82-0.85; individual comparisons 0.79-0.98).
CONCLUSIONS: Advanced vascular and metabolic perfusion biomarkers enabled multidimensional tumor profiling beyond conventional CBV, achieving high and reproducible diagnostic performance across acquisition parameters and providing a potential framework for robust presurgical DSC-PWI assessment of the main adult brain tumors.
引用
- García-Hidalgo, Naval-Baudin, García-García, et al. Dynamic susceptibility contrast perfusion-weighted imaging (DSC-PWI) vascular and metabolic biomarkers for presurgical diagnosis of adult brain tumors across different acquisition parameters. Eur J Radiol. 2026. PMID: 42721920. doi:10.1016/j.ejrad.2026.113218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。